EMEA-002140-PIP01-17
Key facts
| Active substance |
fluticasone propionate
|
| Therapeutic area |
Pneumology-allergology
|
| Decision number |
P/0265/2017
|
| PIP number |
EMEA-002140-PIP01-17
|
| Pharmaceutical form(s) |
Inhalation powder
|
| Condition(s) / indication(s) |
Treatment of asthma
|
| Route(s) of administration |
Inhalation use
|
| Contact for public enquiries |
Teva Pharmaceuticals Europe B.V.
Tel. +44 (0)20 7540 7117
E-mail: medinfo@tevauk.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|